GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization

Kung Hao Liang, Chih Lang Lin, Sung Fang Chen, Chih Wei Chiu, Pei Ching Yang, Ming Ling Chang, Chen Chun Lin, Kai Feng Sung, Cassandra Yeh, Chien Fu Hung, Rong Nan Chien, Chau Ting Yeh

研究成果: 雜誌貢獻文章

6 引文 (Scopus)

摘要

Aim: Transcatheter arterial chemoembolization is currently the standard treatment in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer stage B. Genomic variants of GALNT14 were recently identified as effective predictors for chemotherapy responses in Barcelona Clinic Liver Cancer stage C patients. Methods: We investigated the prognosis predictive value of GALNT14 genotypes in 327 hepatocelluar carcinoma patients treated by transcatheter arterial chemoembolization. Result: Cox proportional hazards model analysis showed that the genotype 'TT' was associated with shorter time-to-response (multivariate p < 0.001), time-to-complete-response (p = 0.004) and longer time-to-tumor progression (p < 0.001), compared with the genotype 'non-TT'. In patients with albumin <3.5 g/dl, genotype 'TT' was associated with longer overall survival (p = 0.027). Finally, genotype 'TT' correlated with higher cancer-to-noncancer ratios of GALNT14 protein levels, lower cancer-to-noncancer ratios of antiapoptotic cFLIP-S, and a clustered glycosylation pattern in the extracellular domain of death receptor 5. Conclusion: GALNT14 genotypes were significantly associated with clinical outcomes of transcatheter arterial chemoembolization. The differential status of extrinsic apoptotic signaling between cancerous and non-cancerous tissues might underlie the clinical association.

原文英語
頁(從 - 到)353-366
頁數14
期刊Pharmacogenomics
17
發行號4
DOIs
出版狀態已發佈 - 2016 三月 1

指紋

Hepatocellular Carcinoma
Genotype
Liver Neoplasms
Therapeutics
TNF-Related Apoptosis-Inducing Ligand Receptors
Neoplasms
Glycosylation
Proportional Hazards Models
Albumins
Carcinoma
Drug Therapy
Survival
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

引用此文

GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. / Liang, Kung Hao; Lin, Chih Lang; Chen, Sung Fang; Chiu, Chih Wei; Yang, Pei Ching; Chang, Ming Ling; Lin, Chen Chun; Sung, Kai Feng; Yeh, Cassandra; Hung, Chien Fu; Chien, Rong Nan; Yeh, Chau Ting.

於: Pharmacogenomics, 卷 17, 編號 4, 01.03.2016, p. 353-366.

研究成果: 雜誌貢獻文章

Liang, KH, Lin, CL, Chen, SF, Chiu, CW, Yang, PC, Chang, ML, Lin, CC, Sung, KF, Yeh, C, Hung, CF, Chien, RN & Yeh, CT 2016, 'GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization', Pharmacogenomics, 卷 17, 編號 4, 頁 353-366. https://doi.org/10.2217/pgs.15.179
Liang, Kung Hao ; Lin, Chih Lang ; Chen, Sung Fang ; Chiu, Chih Wei ; Yang, Pei Ching ; Chang, Ming Ling ; Lin, Chen Chun ; Sung, Kai Feng ; Yeh, Cassandra ; Hung, Chien Fu ; Chien, Rong Nan ; Yeh, Chau Ting. / GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. 於: Pharmacogenomics. 2016 ; 卷 17, 編號 4. 頁 353-366.
@article{57545d64ef9746fe928c545b10e87880,
title = "GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization",
abstract = "Aim: Transcatheter arterial chemoembolization is currently the standard treatment in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer stage B. Genomic variants of GALNT14 were recently identified as effective predictors for chemotherapy responses in Barcelona Clinic Liver Cancer stage C patients. Methods: We investigated the prognosis predictive value of GALNT14 genotypes in 327 hepatocelluar carcinoma patients treated by transcatheter arterial chemoembolization. Result: Cox proportional hazards model analysis showed that the genotype 'TT' was associated with shorter time-to-response (multivariate p < 0.001), time-to-complete-response (p = 0.004) and longer time-to-tumor progression (p < 0.001), compared with the genotype 'non-TT'. In patients with albumin <3.5 g/dl, genotype 'TT' was associated with longer overall survival (p = 0.027). Finally, genotype 'TT' correlated with higher cancer-to-noncancer ratios of GALNT14 protein levels, lower cancer-to-noncancer ratios of antiapoptotic cFLIP-S, and a clustered glycosylation pattern in the extracellular domain of death receptor 5. Conclusion: GALNT14 genotypes were significantly associated with clinical outcomes of transcatheter arterial chemoembolization. The differential status of extrinsic apoptotic signaling between cancerous and non-cancerous tissues might underlie the clinical association.",
keywords = "apoptosis, death receptor, O-glycosylation, sorafenib",
author = "Liang, {Kung Hao} and Lin, {Chih Lang} and Chen, {Sung Fang} and Chiu, {Chih Wei} and Yang, {Pei Ching} and Chang, {Ming Ling} and Lin, {Chen Chun} and Sung, {Kai Feng} and Cassandra Yeh and Hung, {Chien Fu} and Chien, {Rong Nan} and Yeh, {Chau Ting}",
year = "2016",
month = "3",
day = "1",
doi = "10.2217/pgs.15.179",
language = "English",
volume = "17",
pages = "353--366",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization

AU - Liang, Kung Hao

AU - Lin, Chih Lang

AU - Chen, Sung Fang

AU - Chiu, Chih Wei

AU - Yang, Pei Ching

AU - Chang, Ming Ling

AU - Lin, Chen Chun

AU - Sung, Kai Feng

AU - Yeh, Cassandra

AU - Hung, Chien Fu

AU - Chien, Rong Nan

AU - Yeh, Chau Ting

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aim: Transcatheter arterial chemoembolization is currently the standard treatment in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer stage B. Genomic variants of GALNT14 were recently identified as effective predictors for chemotherapy responses in Barcelona Clinic Liver Cancer stage C patients. Methods: We investigated the prognosis predictive value of GALNT14 genotypes in 327 hepatocelluar carcinoma patients treated by transcatheter arterial chemoembolization. Result: Cox proportional hazards model analysis showed that the genotype 'TT' was associated with shorter time-to-response (multivariate p < 0.001), time-to-complete-response (p = 0.004) and longer time-to-tumor progression (p < 0.001), compared with the genotype 'non-TT'. In patients with albumin <3.5 g/dl, genotype 'TT' was associated with longer overall survival (p = 0.027). Finally, genotype 'TT' correlated with higher cancer-to-noncancer ratios of GALNT14 protein levels, lower cancer-to-noncancer ratios of antiapoptotic cFLIP-S, and a clustered glycosylation pattern in the extracellular domain of death receptor 5. Conclusion: GALNT14 genotypes were significantly associated with clinical outcomes of transcatheter arterial chemoembolization. The differential status of extrinsic apoptotic signaling between cancerous and non-cancerous tissues might underlie the clinical association.

AB - Aim: Transcatheter arterial chemoembolization is currently the standard treatment in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer stage B. Genomic variants of GALNT14 were recently identified as effective predictors for chemotherapy responses in Barcelona Clinic Liver Cancer stage C patients. Methods: We investigated the prognosis predictive value of GALNT14 genotypes in 327 hepatocelluar carcinoma patients treated by transcatheter arterial chemoembolization. Result: Cox proportional hazards model analysis showed that the genotype 'TT' was associated with shorter time-to-response (multivariate p < 0.001), time-to-complete-response (p = 0.004) and longer time-to-tumor progression (p < 0.001), compared with the genotype 'non-TT'. In patients with albumin <3.5 g/dl, genotype 'TT' was associated with longer overall survival (p = 0.027). Finally, genotype 'TT' correlated with higher cancer-to-noncancer ratios of GALNT14 protein levels, lower cancer-to-noncancer ratios of antiapoptotic cFLIP-S, and a clustered glycosylation pattern in the extracellular domain of death receptor 5. Conclusion: GALNT14 genotypes were significantly associated with clinical outcomes of transcatheter arterial chemoembolization. The differential status of extrinsic apoptotic signaling between cancerous and non-cancerous tissues might underlie the clinical association.

KW - apoptosis

KW - death receptor

KW - O-glycosylation

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84960918839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960918839&partnerID=8YFLogxK

U2 - 10.2217/pgs.15.179

DO - 10.2217/pgs.15.179

M3 - Article

C2 - 26871639

AN - SCOPUS:84960918839

VL - 17

SP - 353

EP - 366

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 4

ER -